• Home
  • Our Pipeline
  • About Us
  • Science
    • Active Immunotherapies
    • GlyMab®
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Publications
  • Contact Us
    • Find a trial
    • Become an Investigator

Cancer vaccine data due soon; Glymab developments too

by chantal | Jul 10, 2025 | GlyMab, iSCIB1+, Modi-1, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell’s Modi-1 Moditope Vaccine Achieves Early Clinical Validation in Head and Neck Cancer

by chantal | Jan 9, 2025 | Latest News, Modi-1, Moditope, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell founder says the company is ready to commercialise novel medicines to counteract cancer

by admin | Jun 18, 2024 | Interviews, Latest News, Media Coverage, Modi-1, SCIB1

Scancell founder says the company is ready to commercialise novel medicines to counteract cancer Scancell’s Chief Executive Officer, Lindy Durrant, recently sat down with Sarah Lowther from focusIR. During the interview Lindy highlights Scancell’s innovative...

21st Association for Cancer Immunotherapy (CIMT) Annual Meeting, Mainz, May 2024

by chantal | Jun 11, 2024 | Modi-1, SCIB1, Vaccines

21st Association for Cancer Immunotherapy (CIMT) Annual Meeting, Mainz, May 2024 A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma Samantha Paston, Heather Shaw, Poulam Patel, Miranda...

Scancell receives MHRA approval to expand ModiFY trial

by admin | May 30, 2024 | Latest News, Modi-1, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell to present at the Annual Immuno-Oncology Summit Europe

by admin | Apr 17, 2024 | Immunobody, Latest News, Modi-1, Regulatory News, SCIB1

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
« Older Entries

Recent Posts

  • Scancell announces CFO Transition
  • Edison Report – Redesigning immunity: The next frontier in immuno-oncology
  • Scancell Financial Year 2026 Interim Results
  • H126: solid iSCIB1+ data underpins planned progress
  • Interim Results and Business Update

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

About Us
Leadership Team
Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy